Neurocrine Biosciences (NBIX) 21.97 $NBIX
Biotech Equities Update - Biogen Idec, ACADIA Pharma, Halozyme Therapeutics, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Fri Dec 12, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Halozyme Therapeutics Inc. (NASDAQ: HALO), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, December 11, 2014, the NASDAQ Composite ended at 4,708.16, up 0.52%, the Dow Jones Industrial Average advanced 0.36%, to finish the day at 17,596.34, and the S&P 500 closed at 2,035.33, up 0.45%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index also advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
BLUE: 91.28 (+5.16), BIIB: 344.49 (+2.16), ACAD: 32.53 (-0.10), NBIX: 21.97 (+0.12), HALO: 7.99 (-0.16)
Nasdaq stocks posting largest percentage increases
AP - Thu Dec 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SOFO: 7.74 (-2.37), NBIX: 21.97 (+0.12), DERM: 20.00 (-0.92), CHKE: 20.15 (-0.43), LAYN: 8.22 (+0.46), NDQ.TO: 20.33 (+0.28), CLDN: 17.25 (+0.75), NVDQ: 17.58 (+0.08), OBAS: 7.98 (-0.23)
Just Released: New Research on American Airlines, Staples, Cyren, Neurocrine Biosciences, and Cherokee
PR Newswire - Thu Dec 11, 8:17AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations. Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only. To access our full PDF reports on a complementary basis, please visit the links below.
NBIX: 21.97 (+0.12)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/srj257/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Addex Therapeutics - Azevan Pharmaceuticals - Catalyst Pharmaceutical Partners - Humanetics Corporation - Intra-Cellular Therapies - Marinus Pharmaceuticals - Nanotherapeutics - Neuralstem - Neurocrine Biosciences - NeuroNascent - Omeros Corporation - Otsuka Holdings - Pfizer - Polleo Pharma - Tonix Pharmaceuticals Holding - Vanda Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/sr...ttraumatic
NBIX: 21.97 (+0.12), TNXP: 6.30 (-0.36), MRNS: 7.63 (-0.50), CPRX: 2.87 (+0.01), VNDA: 12.72 (-0.17), ITCI: 15.79 (-0.47), OMER: 22.81 (+0.12)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 4:39PM CST
RH: 93.59 (-0.40), BXS: 21.41 (+0.10), NBIX: 21.97 (+0.12), BDC: 80.41 (+0.02), GDP: 3.93 (-0.33), APT: 2.64 (-0.03), AUQ: 3.30 (-0.02), LAKE: 10.79 (-0.40), SFUN: 7.73 (+0.06), AGI: 7.04 (-0.20)
Uptrend Call Working As Neurocrine Biosciences Stock Rises 17.7% (NBIX)
Comtex SmarTrend(R) - Wed Dec 10, 10:00AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 2 months, Neurocrine Biosciences has returned 17.65% as of today's recent price of $19.86.
NBIX: 21.97 (+0.12)
Neurocrine Biosciences Announces Expansion of its Clinical Pipeline
PR Newswire - Wed Dec 10, 7:00AM CST
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has entered clinical trials for the treatment of classic congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States. The Company has successfully completed a pilot clinical trial in adults with classic CAH and is initiating an open-label, single ascending dose trial in approximately fifteen adolescent females with classic CAH, the 1401 Study.
NBIX: 21.97 (+0.12)
Clinovo Presents Its Cloud-Based EDC System ClinCapture at the San Diego Clinical Research Network Event in San Diego
PRWeb - Mon Dec 08, 2:12AM CST
Clinovo presents its cloud-based technology and EDC solution ClinCapture at the San Diego Clinical Research Network event in San Diego on December 9th, 2014. This program provides an introduction to using the cloud in the life sciences and clinical trials.
NBIX: 21.97 (+0.12)
Neurocrine Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference
PR Newswire - Thu Dec 04, 6:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 25th Annual Oppenheimer Healthcare Conference in New York City.
NBIX: 21.97 (+0.12)
17.3% Return Seen to Date on SmarTrend Neurocrine Biosciences Call (NBIX)
Comtex SmarTrend(R) - Wed Dec 03, 9:22AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 2 months, Neurocrine Biosciences has returned 17.30% as of today's recent price of $19.80.
NBIX: 21.97 (+0.12)
Neurocrine to Present at the 2014 Deutsche Bank BioFEST and the 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Tue Nov 25, 12:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at two investor conferences next week.
NBIX: 21.97 (+0.12), DB: 30.78 (-0.56)
Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel
Business Wire - Wed Nov 19, 7:01AM CST
Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Margaret Valeur-Jensen, Ph.D. to the newly created position of General Counsel, effective immediately. She will be responsible for providing legal advice regarding the Company's commercial operations, research activities, business development and compliance with industry standards.
NBIX: 21.97 (+0.12), RTRX: 10.12 (+0.24), AMGN: 164.53 (-1.55)
Neurocrine Biosciences Has Returned 13.2% Since SmarTrend Recommendation (NBIX)
Comtex SmarTrend(R) - Tue Nov 18, 11:13AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 1 month, Neurocrine Biosciences has returned 13.15% as of today's recent price of $19.10.
NBIX: 21.97 (+0.12)
Post Earnings Update: Neurocrine Biosciences Has Climbed 4.2% Higher in Past 2 Weeks (NBIX)
Comtex SmarTrend(R) - Mon Nov 17, 4:01PM CST
When Neurocrine Biosciences (NASDAQ:NBIX) reported earnings two weeks ago on November 3rd, 2014, analysts, on average, expected the company to report a loss of $0.21 on sales of $0.0 thousand. Neurocrine Biosciences actually reported a loss of $0.21 per share on sales of $0.0 thousand, matching EPS estimates and matching revenue estimates. Shares of Neurocrine Biosciences have climbed from $18.15 to $18.92, representing a gain of 4.2% since the company reported earnings 14 days ago.
NBIX: 21.97 (+0.12)
Neurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference
PR Newswire - Wed Nov 12, 12:56PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2014 Global Healthcare Conference in London.
NBIX: 21.97 (+0.12)
Neurocrine Biosciences Looking Forward To A Big Year
Stephen Simpson, CFA - at Seeking Alpha - Thu Nov 06, 10:57AM CST
NBIX: 21.97 (+0.12), ABBV: 65.27 (-1.76)
Neurocrine Biosciences, Inc. Announces Appointment of Darin Lippoldt as Chief Legal Officer
PR Newswire - Tue Nov 04, 6:30AM CST
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Darin Lippoldt has joined the executive management team as Chief Legal Officer.
NBIX: 21.97 (+0.12)
Biotech Equities Update - Biogen Idec, ACADIA Pharma, Halozyme Therapeutics, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Fri Dec 12, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Halozyme Therapeutics Inc. (NASDAQ: HALO), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, December 11, 2014, the NASDAQ Composite ended at 4,708.16, up 0.52%, the Dow Jones Industrial Average advanced 0.36%, to finish the day at 17,596.34, and the S&P 500 closed at 2,035.33, up 0.45%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index also advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
BLUE: 91.28 (+5.16), BIIB: 344.49 (+2.16), ACAD: 32.53 (-0.10), NBIX: 21.97 (+0.12), HALO: 7.99 (-0.16)
Nasdaq stocks posting largest percentage increases
AP - Thu Dec 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SOFO: 7.74 (-2.37), NBIX: 21.97 (+0.12), DERM: 20.00 (-0.92), CHKE: 20.15 (-0.43), LAYN: 8.22 (+0.46), NDQ.TO: 20.33 (+0.28), CLDN: 17.25 (+0.75), NVDQ: 17.58 (+0.08), OBAS: 7.98 (-0.23)
Just Released: New Research on American Airlines, Staples, Cyren, Neurocrine Biosciences, and Cherokee
PR Newswire - Thu Dec 11, 8:17AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations. Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only. To access our full PDF reports on a complementary basis, please visit the links below.
NBIX: 21.97 (+0.12)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/srj257/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Addex Therapeutics - Azevan Pharmaceuticals - Catalyst Pharmaceutical Partners - Humanetics Corporation - Intra-Cellular Therapies - Marinus Pharmaceuticals - Nanotherapeutics - Neuralstem - Neurocrine Biosciences - NeuroNascent - Omeros Corporation - Otsuka Holdings - Pfizer - Polleo Pharma - Tonix Pharmaceuticals Holding - Vanda Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/sr...ttraumatic
NBIX: 21.97 (+0.12), TNXP: 6.30 (-0.36), MRNS: 7.63 (-0.50), CPRX: 2.87 (+0.01), VNDA: 12.72 (-0.17), ITCI: 15.79 (-0.47), OMER: 22.81 (+0.12)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 4:39PM CST
RH: 93.59 (-0.40), BXS: 21.41 (+0.10), NBIX: 21.97 (+0.12), BDC: 80.41 (+0.02), GDP: 3.93 (-0.33), APT: 2.64 (-0.03), AUQ: 3.30 (-0.02), LAKE: 10.79 (-0.40), SFUN: 7.73 (+0.06), AGI: 7.04 (-0.20)
Uptrend Call Working As Neurocrine Biosciences Stock Rises 17.7% (NBIX)
Comtex SmarTrend(R) - Wed Dec 10, 10:00AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 2 months, Neurocrine Biosciences has returned 17.65% as of today's recent price of $19.86.
NBIX: 21.97 (+0.12)
Neurocrine Biosciences Announces Expansion of its Clinical Pipeline
PR Newswire - Wed Dec 10, 7:00AM CST
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has entered clinical trials for the treatment of classic congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States. The Company has successfully completed a pilot clinical trial in adults with classic CAH and is initiating an open-label, single ascending dose trial in approximately fifteen adolescent females with classic CAH, the 1401 Study.
NBIX: 21.97 (+0.12)
Clinovo Presents Its Cloud-Based EDC System ClinCapture at the San Diego Clinical Research Network Event in San Diego
PRWeb - Mon Dec 08, 2:12AM CST
Clinovo presents its cloud-based technology and EDC solution ClinCapture at the San Diego Clinical Research Network event in San Diego on December 9th, 2014. This program provides an introduction to using the cloud in the life sciences and clinical trials.
NBIX: 21.97 (+0.12)
Neurocrine Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference
PR Newswire - Thu Dec 04, 6:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 25th Annual Oppenheimer Healthcare Conference in New York City.
NBIX: 21.97 (+0.12)
17.3% Return Seen to Date on SmarTrend Neurocrine Biosciences Call (NBIX)
Comtex SmarTrend(R) - Wed Dec 03, 9:22AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 2 months, Neurocrine Biosciences has returned 17.30% as of today's recent price of $19.80.
NBIX: 21.97 (+0.12)
Neurocrine to Present at the 2014 Deutsche Bank BioFEST and the 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Tue Nov 25, 12:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at two investor conferences next week.
NBIX: 21.97 (+0.12), DB: 30.78 (-0.56)
Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel
Business Wire - Wed Nov 19, 7:01AM CST
Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Margaret Valeur-Jensen, Ph.D. to the newly created position of General Counsel, effective immediately. She will be responsible for providing legal advice regarding the Company's commercial operations, research activities, business development and compliance with industry standards.
NBIX: 21.97 (+0.12), RTRX: 10.12 (+0.24), AMGN: 164.53 (-1.55)
Neurocrine Biosciences Has Returned 13.2% Since SmarTrend Recommendation (NBIX)
Comtex SmarTrend(R) - Tue Nov 18, 11:13AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 1 month, Neurocrine Biosciences has returned 13.15% as of today's recent price of $19.10.
NBIX: 21.97 (+0.12)
Post Earnings Update: Neurocrine Biosciences Has Climbed 4.2% Higher in Past 2 Weeks (NBIX)
Comtex SmarTrend(R) - Mon Nov 17, 4:01PM CST
When Neurocrine Biosciences (NASDAQ:NBIX) reported earnings two weeks ago on November 3rd, 2014, analysts, on average, expected the company to report a loss of $0.21 on sales of $0.0 thousand. Neurocrine Biosciences actually reported a loss of $0.21 per share on sales of $0.0 thousand, matching EPS estimates and matching revenue estimates. Shares of Neurocrine Biosciences have climbed from $18.15 to $18.92, representing a gain of 4.2% since the company reported earnings 14 days ago.
NBIX: 21.97 (+0.12)
Neurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference
PR Newswire - Wed Nov 12, 12:56PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2014 Global Healthcare Conference in London.
NBIX: 21.97 (+0.12)
Neurocrine Biosciences Looking Forward To A Big Year
Stephen Simpson, CFA - at Seeking Alpha - Thu Nov 06, 10:57AM CST
NBIX: 21.97 (+0.12), ABBV: 65.27 (-1.76)
Neurocrine Biosciences, Inc. Announces Appointment of Darin Lippoldt as Chief Legal Officer
PR Newswire - Tue Nov 04, 6:30AM CST
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Darin Lippoldt has joined the executive management team as Chief Legal Officer.
NBIX: 21.97 (+0.12)
